<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943420</url>
  </required_header>
  <id_info>
    <org_study_id>BE2017770</org_study_id>
    <nct_id>NCT03943420</nct_id>
  </id_info>
  <brief_title>One Research on Improving Cognitive Impairment Caused by Hypertension</brief_title>
  <official_title>One Research on Application of Key Technologies About Improving Cognitive Impairment Caused by Hypertension With the Therapy of Early Intervention With Qianyang Yuyin Granules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Famous Medical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Famous Medical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using the therapy of early intervention with Qianyang Yuyin Granules to improve cognitive
      impairment caused by hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using the therapy of early intervention with Qianyang Yuyin Granules to improve cognitive
      impairment caused by hypertension.

      The investigators designed a multi-center randomized controlled clinical trial to study the
      security and effectiveness of this therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Changes of brain image</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measure and record the volume changes of diseased alba, the micro-structure changes of alba fasciculus by MRI to see if the therapy effect or not.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure and assess the changes of VaDAS-cog ( Vascular Dementia Assessment Scale cognitive subscale ) among time points</measure>
    <time_frame>12 weeks, 24 weeks, 48 weeks</time_frame>
    <description>Measure and record with VaDAS-cog</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure and assess the changes of MMSE ( Mini-mental State Examination ) among time points</measure>
    <time_frame>12 weeks, 24 weeks, 48 weeks</time_frame>
    <description>Measure and record with MMSE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure and assess the changes of ADL ( Activity of Daily Living ) among time points</measure>
    <time_frame>12 weeks, 24 weeks, 48 weeks</time_frame>
    <description>Measure and record with ADL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure and assess the changes of CDR ( Clinical Dementia Rating ) among time points</measure>
    <time_frame>12 weeks, 24 weeks, 48 weeks</time_frame>
    <description>Measure and record with CDR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of outcome event</measure>
    <time_frame>24 weeks</time_frame>
    <description>Record the outcome event and analyse the incidence rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic effect</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measure and record patients' systolic and diastolic blood pressure and analyse related data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabonomics</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measure and record the metabonomics ( Trx &amp; TrxR ) index</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <description>Therapy A : Basic treatment + Qianyang Yuyin Granules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative Control Group</arm_group_label>
    <description>Therapy B : Basic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive Control Group</arm_group_label>
    <description>Therapy C : Basic treatment + Donepezil</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample; Urine sample.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cognitive impairment caused by hypertension.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 55 to 75 years old, male or female;

          -  Having a history of hypertension for more than 2 years but can maintain SBP ≤ 140 mmHg
             and BDP ≤ 90 mmHg with medication；

          -  21 ≤ MMSE ＜ 26, or 14 ≤ MoCA ＜ 26, CDR ＜ 0.5. Bseides, the chief complaint must happen
             after having hypertension；

          -  Meet TCM Syndrome Differentiation Standard：according to the Guidelines for the
             Clinical Research of Chinese Medicine New Drugs ( published by China Medical Science
             Press ) ：Overabundant liver-fire type：dizziness and headache, both face and eyes are
             red, dry mouth and bitter taste in mouth, red tongue with yellowish coating, wire and
             frequent pulse. Yin deficiency and yang hyperactivity type: dizziness and headache,
             Tinnitus and forgetfulness, sphoria with feverish sensation in chest &amp; palms &amp; soles,
             palpitation and insomnia, red tongue &amp; thin white or less coating, wiry weak and
             numbered pulse；

          -  CTMRI hint: leukoaraiosis and no sign of Cerebral infarction；

          -  Patients or the guardian hold the right opinions over the research and are willing to
             obey researcher's orders；

          -  Having a certain degree of education (being able to read simple newspapers in the
             past)；

          -  Patients agree to sign informed consent。

        Exclusion Criteria:

          -  Secondary hypertension；

          -  Taking certain kinds of antihypertensive drugs which may damage brain cognitive
             function；

          -  Diagnosed as depression or other mental disorders according to DSM-IV；

          -  Diagnosed as vascular dementia according to diagnostic criteria, CDR ≥ 0.5; alzheimer
             disease or dementia caused by some other reasons (including mixed dementia according
             to diagnostic criteria for VCI); cognitive impairment due to head injury。

          -  Suffering from certain kinds of diseases which may interfere the assessment of
             cognitive function, including those who are diagnosed as alcoholics and drugs or
             psychotropic medicine abusers during the last 5 years according to DSM-IV；

          -  Accompanied with severe neurological function disorder；

          -  Asthma, chronic severe primary cardiovascular disease, liver lesion, hematological
             lesions, lung diseases, diabetes or other severe diseases may influence the patients'
             survival such as cancer or AIDS；

          -  Other: Such as poor compliance, or can not attend the follow-up visit in time for some
             reasons；

          -  Taking the same kind of medicine during the last 30 days which may influence the
             trial；

          -  Is participating in another clinical study；

          -  Not up to TCM Syndrome Differentiation Standard。
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cheng Chang, PhD</last_name>
    <phone>+8613851821996</phone>
    <email>chch1967@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jiangsu Province Hospital of Chinese Medcine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Chang, PhD</last_name>
      <phone>+8613851821996</phone>
      <email>chch1967@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Therapy</keyword>
  <keyword>Qianyang Yuyin Granules</keyword>
  <keyword>Cognitive impairment</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

